Explore the Agenda
7:30 am Check-In & Light Refreshments
Discovery, Design & Engineering
Workshop A
8:30 am Harnessing Precision Synapse Engineering by Designing Condition Specific Co- Stimulation to Advance Therapeutic Windows
Join this workshop to navigate the engineering trade-offs required to unlock the potential of costimulatory engagers in solid tumors.
- Discussing criteria for the selection of high value targets that require conditional activation to protect healthy tissue
- Analyzing the pros and cons of masking the TAA binder versus the CD3 binder
- Identifying the most robust protease-cleavable linkers and stable building blocks
- Discussing models to stimulate the human TME protease levels
- Strategies for evaluating the PK of post-cleaved active product vs pro-drug masked state
- Defining minimum preclinical data set required to justify the complexity of a conditional molecule over a regular one
Preclinical, Translational & Clinical
Workshop D
8:30 am Navigating Oncology & Autoimmunity Divergence by Tailoring Multi-Lineage Engagement to Achieve Durable Immune Reset
Join this workshop to explore the diverging pathways of drug development when T-Cell Engagers are applied to either lifethreatening malignancies or chronic autoimmune conditions.
- Analyzing the dual-target potential of CD38 to achieve deep plasma cell depletion and debating how the shift from oncology-level remission to autoimmune level long-term safety alters the risk benefit profile for chronic conditions
- Exploring alternative non-clinical models to prioritize immune restoration over cell depletion and debating the validity of NHP studies for predicting long-term tolerance
- Benchmarking MABEL-based dosing strategies in nonterminal patients and assessing computational modelling as a tool to bridge the gap between oncology’s toxicity-driven and autoimmunity’s safety-driven thresholds
- Evaluating the translational evidence required to justify the risk of chronic exposure and addressing the predictive limitations of traditional oncology safety packages for autoimmune use
10:30 am Morning Break & Networking
Workshop B
11:00 am Engineering Molecular Geometry to Optimize Multispecific T-Cell Engagers for Better Developability
Join this workshop to master the structural complexity of next generation multispecifics, where the focus shifts from simple binding to the precise spatial coordination of the immunological synapse.
- Designing trispecifics that require two tumor antigens to trigger engagement, widening the therapeutic window
- Engineering trispecifics that require two different tumor antigens to trigger CD3 engagement, significantly widening the therapeutic index for antigens
- Overcoming engineering hurdles to ensure the two components of the TCE only meet on the tumor cell surface
- Technical deep-dive into target identification using TCR-target discovery engines to reduce minimal off-target reactivity
- Identifying the optimal inter-membrane distance and how the choice of epitopes on the tumor antigen dictates efficacy
Workshop E
11:00 am Revolutionizing Bench to Bedside Transitions by Optimizing a Comprehensive Translational Package to Accelerate Clinical Entry
Join this workshop to bridge the critical gap between preclinical promise and clinical reality, where the focus shifts from molecular potency to the power of a translational data package
- Discussing ideal assays for bankable safety data beyond TCRs, such as cytokine release assays and tissue models
- Evaluating the translational impact of Fc-silencing or Fcengineering on systemic inflammation and half-life in a nonanimal context
- Discussing the current gap in translational models for ICANS/ neurotoxicity and whether specialized neuro models are ready for IND inclusion
- Deep diving into how TCE developers are harnessing the modified MABEL approach to avoid ‘sub-therapeutic’ dose escalation and save cohorts
- Discussing how unexpected clinical outcomes should trigger new in vitro or ex vivo studies
1:00 pm Lunch & Networking
Workshop C
2:00 pm Transforming Precision Targeting by Leveraging AI-Driven Antigen Selection to Enable Highly Accurate TCE Design
Join this workshop to move beyond the “AI buzzword” and confront the biological hurdles of antigen heterogeneity. As we pivot toward more complex engineering, this session addresses the critical uncertainty of target density: determining whether 20% or 80% cellular expression is the threshold for clinical success.
- Using machine learning to synthesize datasets to profile antigen prevalence across primary vs. metastatic tissues
- Identifying which novel targets are tumor-specific versus those with risky low-level expression in healthy tissues
- Deep-diving into the antigen expression level needed to trigger the action of a T-cell engager
- Developing AI algorithms that move beyond simple “positive/ negative” IHC scores to more predictive “probability of response” scores based on complex expression patterns
- Discussing how clinical trial failures can be fed back into AI models to refine the next generation of discovery
Workshop F
2:00 pm Synchronizing Global Regulatory Strategies by Navigating Non-Clinical Discrepancies to Expedite Global Approval of Next-Generation TCEs
Join this workshop to navigate the shifting regulatory landscape for non-clinical safety, where the focus moves from traditional animal-heavy packages to a weight of evidence framework.
- Discussing policy inconsistencies across health authorities regarding animal usage, focussing on non-human primate studies
- Exploring ‘weight of evidence’ approaches for well-established or characterized targets to potentially waive or refine studies
- Debating scientific examples such as the necessity of repeated NHP studies for new generations of B-cell depleting CD3 T-cell engagers
- Uncovering the possibility of referencing marketed products for weight of evidence studies
- Advancing the idea of a ‘bridging study’ via in vitro comparative data rather than a full GLP NHP study when a new molecule only has slightly modified Fc regions